Skip Ribbon Commands
Skip to main content
Dr Kelvin Teo

Dr Teo Kelvin

​MBBS, M Med(Ophth), FAMS

Senior Consultant

Singapore National Eye Centre

Specialty: Medical Retina

Sub-specialties: Medical Retina

Clinical Appointments

  • Senior Consultant Medical Retina Department Singapore National Eye CentreSingapore National Eye Centre
  • Clinical Director SNEC Ocular Reading Centre (SORC) Singapore National Eye CentreSingapore National Eye Centre
  • Director, Transformation & Innovation, Office of Strategy, Innovation & Organisation Transformation Singapore National Eye CentreSingapore National Eye Centre
  • Senior Consultant SNEC Eye Clinic @ CGH Changi General HospitalChangi General Hospital

Academic Appointments

  • Associate Professor SingHealth Duke-NUS Ophthalmology & Visual Sciences Academic Clinical Programme


​Dr Kelvin Teo has a strong interest in clinical research in the field of medical retina. In particular, his focus is on real world outcomes and how imaging techniques help to advance the pathophysiology and therapy of neovascular age related macular degeneration.


  • FAMS
  • M Med(Ophth) (2016)
  • MBBS (2010)

Professional Appointments and Committee Memberships


  • Best presentation, 2nd place, Annual HDR symposium, Vision Science and Ophthalmology, Save Sight Institute, University of Sydney (2018)
  • MIT best presentation, The Association for Research in Vision & Ophthalmology (ARVO), (2018)
  • Best poster 2nd place, The 10th Congress of the Asia-Pacific Vitreo-retina Society (APVRS) (2016)

Research Interests

  • Real world outcomes for retina disease from registry data

  • Imaging for retina disease

  • Gene therapy for retina disease


  1. Comparison of optical coherence tomography angiographic changes after anti-vascular endothelial growth factor therapy alone or in combination with photodynamic therapy in polypoidal choroidal vasculopathy Teo KYC, Yanagi Y, Lee SY, Yeo IYS, Tan GSW, Mathur R, Chan CM, Wong TY, Cheung CMG. Retina. 2017 Aug 1. doi: 10.1097/IAE.0000000000001776

  2. Teo KY, Ng WY, Lee SY, Cheung GCM. Management of myopic choroidal neovascularization: Focus on Anti-VEGF therapy drugs, 2016, DOI 10.1007/s40265-016-0605-0

  3. Iseato Y, Yuda K, Teo KY, Tan X, Murata T, Shindo T, Yanagi Y. Adrenomedullin: A potential therapeutic target for retinochorodial disease.  Prog Retin Eye Res, 2016, May; 52:112-29. Doi:10.1016/j.preteyeres.2016.01.001. Epub 2016 Jan 12

  4. Tan AC, Teo K, Guan OS, Koh A. Long-term outcomes of myopic choroidal neovascularisation treated with combined ranibizumab and dexamethasone characterised by multi-modal imaging. Graefes Arch Clin Exp Ophthalmol. 2016 Mar [Epub ahead of print] PubMed PMID: 26968717

  5. Chan NS, Teo K, Cheung CM. Epidemiology and diagnosis of myopic choroidal neovascularization in Asia eye contact lens. 2016 Jan;42(1):48-55. doi: 10.1097/ICL.0000000000000201. PubMed PMID: 26448447

Research Trials

  • Real world outcomes in neovascular AMD (2017 - present)
  • Vitreoretinal interface abnormalities as detected on optical coherence tomography: Epidemiology and association with distance vision and health related quality of life (2016 - present)
  • Surgical removal of mechanical barriers to AAV vector delivery in a non-human primate model (2016 -2017)